New phase III data show Roche ’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared toafliberceptMoreVabysmo patients showed an absence of blood vessel leakage in the retina compared toaflibercept in a pre-specified exploratory endpointIf approved, RVO would be the third indication forVabysmo in addition toneovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaBasel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from two global phase III studies, BALATON and COMINO, evaluating Vabysmo ® (faricimab) in macular ...
Source: Roche Media News - February 10, 2023 Category: Pharmaceuticals Source Type: news

Marmite and Dove maker Unilever warns of more price rises this year
Unilever, the company behind brandsincluding Marmite and Dove soap, will continue increasing prices for consumers this year after higher price tags on detergents, soaps and packaged food helped the company beat sales forecasts for 2022. The London-headquartered company warned that “underlying…#unilever #hellmans #benjerrys #ukraine #domestos #alanjope
Source: Reuters: Health - February 9, 2023 Category: Consumer Health News Source Type: news

A construction accident prevention system based on the Internet of Things (IoT) - Zhang M, Ghodrati N, Poshdar M, Seet BC, Yongchareon S.
In recent years, emerging sensing and detection technologies have been adopted to enhance safety in many construction sites. In this paper, we proposed to use a radio frequency identification (RFID) system, which consists of RFID readers, semi-passive tags...
Source: SafetyLit - February 6, 2023 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news

European Commission approves label expansion of Roche ’s Hemlibra to include people with moderate haemophilia A in the EU
Hemlibra, already approved for severe haemophilia A in the EU, will now also provide an effective and convenient prophylactic treatment option for people with moderate haemophilia AModerate haemophilia A can have a significant impact on the lives of people affected, with only 15% living a bleed-free life1The approval is based on the HAVEN 6 results, whereHemlibra demonstrated effective bleed control and a favourable safety profile in people with moderate haemophilia A without inhibitors2Basel, 01 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission approved the expansion of the He...
Source: Roche Investor Update - February 1, 2023 Category: Pharmaceuticals Source Type: news

Bitcoin sees most long liquidations of 2023 as BTC price tags $22.5K
swapped bullish gains for chop into Jan. 31 as the end of the month saw nervous price action. Data from Cointelegraph Markets Pro and TradingView tracked a less confident BTC/USD as it briefly wicked to just above $22,500 on Bitstamp overnight. A rebound saw the pair flip $23,000 to short-term…#tradingview #btcusd #bitstamp #europeancentralbank #bitcoin #coinglass #btc #twitter #bitcoins #kriptomevsimi
Source: Reuters: Health - January 31, 2023 Category: Consumer Health News Source Type: news

Second Phase of the NIH Preprint Pilot Launched
Today, we are pleased to announce the launch of the second phase of the NIH Preprint Pilot with the addition of more than 700 new preprint records to PubMed Central (PMC) and PubMed. This second phase expands the scope of the Pilot to include preprints resulting from all NIH-funded research. Eligible preprints are those acknowledging direct support of an NIH award or authored by NIH staff and posted to bioRxiv, medRxiv, arXiv, or Research Square, on or after January 1, 2023. NLM will automatically include the full text of the preprint (as license terms allow) and associated citation information in PMC and PubMed, respectiv...
Source: PubMed Central News - January 30, 2023 Category: Databases & Libraries Source Type: news

Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

EMR Screening in Emergency Department Tags Undiagnosed Diabetes EMR Screening in Emergency Department Tags Undiagnosed Diabetes
Missed diabetes diagnoses identified by EMR screening were especially common in racial and ethnic minorities.MDedge News
Source: Medscape Medical News Headlines - January 26, 2023 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Why Humans Remember Emotional Events Better
Neuroscientists identify a specific neural mechanism in the human brain that tags information with emotional associations for enhanced memory
Source: Disabled World - January 19, 2023 Category: Disability Tags: The Human Brain Source Type: news

The solution to fashion ’s sustainability crisis may be connected clothing tags
In November, H&M launched a new retail format at its 7,000-square-foot space in Brooklyn’s Williamsburg. Some of the new tech features incorporated in the store’s design include smart mirrors, which can detect the size and color of clothes the customer tries on, and mobile payments enabled around…#nataliemassenets #salvatoreferragamo #rentrunway #yooxnetaporter #alisonloehnis #brooklyn #digitalid #pangaia #eon #franck
Source: Reuters: Health - January 18, 2023 Category: Consumer Health News Source Type: news

Google ' s Nest appears to be working on AirTag-like location trackers, codenamed “Grogu”, with support for Bluetooth LE and UWB, possibly for launch at I/O
Google is reportedly working on a location tracking tag to compete with the likes of Apple’s AirTags and Tile trackers, according to developer (and reliable leaker) Kuba Wojciechowski. Wojciechowski discovered references that indicate Google is working on support for locator tags in Fast Pair —…#groguaudio #nest #uwb #findernetwork #fastpair #tile #nearbyshare #google #twitter #applesairtags
Source: Reuters: Health - January 17, 2023 Category: Consumer Health News Source Type: news

What Are Common Dietary Fermentable Carbohydrates?
Discussion Parents may often come to the pediatrician for concerns about crying and colic, increased belching, abdominal distention, increased flatulence, abdominal pain or stool changes. They complain of increased “gassiness,” which could mean any or a combination of these problems, or something different that they believe is referred to the abdomen. In newborns parents’ intolerance for crying and normal changes in the abdomen (e.g. appearing larger or smaller) may have them complain of “gassiness” but they do not mean actual belching or flatulence. In older children, parents may state that t...
Source: PediatricEducation.org - January 16, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza is the first influenza antiviral with a new mechanism of action in almost 20 years, stopping viral replication faster thanoseltamivirSingle-doseXofluza helps reduce the societal burden of influenza by helping patients recover quickly and by preventing infection in individuals following contact with someone with the virusBasel, 12 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC...
Source: Roche Investor Update - January 12, 2023 Category: Pharmaceuticals Source Type: news

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20